Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Cardio Diagnostics Holdings (CDIOW) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Cardio Diagnostics Holdings (CDIOW) over the last 4 years, with Q3 2025 value amounting to $102010.0.

  • Cardio Diagnostics Holdings' Change in Accured Expenses rose 34884.94% to $102010.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $75926.0, marking a year-over-year increase of 11384.84%. This contributed to the annual value of -$155552.0 for FY2024, which is 8009.57% up from last year.
  • Per Cardio Diagnostics Holdings' latest filing, its Change in Accured Expenses stood at $102010.0 for Q3 2025, which was up 34884.94% from -$59457.0 recorded in Q2 2025.
  • Cardio Diagnostics Holdings' Change in Accured Expenses' 5-year high stood at $482589.0 during Q2 2022, with a 5-year trough of -$379862.0 in Q4 2023.
  • In the last 4 years, Cardio Diagnostics Holdings' Change in Accured Expenses had a median value of -$28340.0 in 2023 and averaged -$49175.1.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 143018.01% in 2023, then soared by 34884.94% in 2025.
  • Cardio Diagnostics Holdings' Change in Accured Expenses (Quarter) stood at -$94956.0 in 2022, then crashed by 300.04% to -$379862.0 in 2023, then skyrocketed by 103.38% to $12853.0 in 2024, then surged by 693.67% to $102010.0 in 2025.
  • Its last three reported values are $102010.0 in Q3 2025, -$59457.0 for Q2 2025, and $20520.0 during Q1 2025.